多药耐药性：难治性幽门螺杆菌感染的临床困境。
Multidrug resistance: The clinical dilemma of refractory Helicobacter pylori infection.
机构信息
Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan; Chang Gung Microbiota Therapy Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
出版信息
J Microbiol Immunol Infect. 2021 Dec;54(6):1184-1187. doi: 10.1016/j.jmii.2021.03.006. Epub 2021 Mar 23.
This study investigated the antimicrobial resistance of isolates from patients with refractory Helicobacter pylori. The resistance rate was 34.1% for amoxicillin, 92.7% for clarithromycin, 65.9% for metronidazole, 85.4% for levofloxacin, and 29.3% for rifabutin. Dual resistance to both clarithromycin and levofloxacin was found in 73.2%. The antimicrobial resistance rate of refractory H. pylori was extremely high, which had become a major consideration in therapeutic challenge.
本研究调查了耐治疗性幽门螺杆菌患者分离株的抗菌药物耐药性。阿莫西林的耐药率为 34.1%，克拉霉素 92.7%，甲硝唑 65.9%，左氧氟沙星 85.4%，利福布汀 29.3%。同时对克拉霉素和左氧氟沙星耐药的比例为 73.2%。耐治疗性幽门螺杆菌的抗菌药物耐药率极高，这已成为治疗挑战的主要考虑因素。
Zotero 插件